At a time when the world of medical imaging is all about artificial intelligence, our aim is to bring it within your reach!
Our technology lets radiologists and clinicians focus on quality of care by building artificial intelligence systems into their workflow, all with a focus on clinical needs.
Our natively AI-powered clinical apps are built to the highest clinical standards.
Innovative, collaborative solutions fully integrated into any healthcare information system
20 years
of innovation
1,200 customers
worldwide
70 employees
committed to saving lives
170 scientific papers
and several technology patents
Intrasense news
Intrasense announces CE certification of Liflow® to the new European regulation (MDR)
29 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.
Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer
24 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.
Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up
16 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.
Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI
8 April 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG […]
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® (the "Company"), today announced its annual 2023 IFRS consolidated financial results certified at Group level.
Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024
26 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).
Intrasense announces the certification of Myrian® to the new European regulation (MDR)
21 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is proud to announce that the company has obtained the new CE certification under MDR (European Union Medical Device Regulation 2017/745), authorizing the marketing of the latest version of its Myrian® solution.
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian® (the "Company"), today announced its 2023 consolidated IFRS revenue (uncertified) at Group level.
Intrasense announces its financial agenda for 2024
31 January 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the dates of its next financial communications for the year 2024.
Intrasense announces strategic partnership with EDL, French leader in digital healthcare solutions
18 October 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, has announced the signature of a strategic partnership with EDL. French leader in software packages for technical platforms of public and private healthcare establishments, EDL develops Xplore®, a radiology solution. This partnership will enable the integration and marketing of Myrian® clinical […]
2023 Half-year results: sales growth and continued investment policy
20 September 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, annonce ses résultats semestriels 2023 consolidés aux normes IFRS. Etant précisé que suite à l’OPA volontaire du groupe Guerbet, clôturée en date du 5 juin 2023, le groupe Intrasense est maintenant intégré dans le périmètre de consolidation du groupe Guerbet.
Intrasense attends the 2023 « Journées Francophones de Radiologie »
13 September 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its attendance in the 2023 “Journées Francophones de la Radiologie” (JFR), where new innovative solutions incorporating artificial intelligence will be presented.
Intrasense signs a strategic contract with Ebit to market its solutions in Italy
11 July 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, and Ebit, part of the italian group Esaote, specialized in the development of software solutions for diagnostic imaging, announce their strategic partnership to market Intrasense solutions in Italy.
Intrasense and Guerbet sign a licensing and integration agreement for artificial intelligence in oncology medical imaging
19 June 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, et Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announce the signature on June 19, 2023 of a license agreement to integrate and market Guerbet's artificial intelligence algorithms within Intrasense software platforms.
Intrasense announces the co-option of a new director and the appointment of a new Chairman of its Board of Directors
25 May 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, annonces, the co-option of a new director to the Board, also appointed Chairman of the Board.
2022 annual results: continued investments and renewed growth ambition
30 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian® (the "Company"), today announced its consolidated (unaudited) 2022 IFRS financial results at Group level.
Intrasense strengthens its porfolio with the signature of a contract with SATT Sud-Est
27 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the signature of a technology transfer contract with SATT Sud-Est that will allow the company to acquire artificial intelligence algorithms dedicated to the detection of pulmonary nodules in radiology. These algorithms were developed by the Medical Imaging Unit of the Assistance Publique-Hôpitaux de […]
Intrasense and the ICM sign a partnership to optimize a new solution dedicated to oncology
6 February 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine.
Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
11 January 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million euros at an issuance price of 0.44 euro per share, […]
